Table 3.
Number and rate of clinical eventsa
| Parameter | TT | CT | CC | P | P (CC versus CT + TT) |
|---|---|---|---|---|---|
| GFR | |||||
| total | 60 (17.4) | 59 (18.3) | 6 (9.2) | 0.20 | 0.08 |
| UP/Cr >0.22b | 34 (32.4) | 36 (34.6) | 5 (31.3) | 0.94 | 0.84 |
| ESRD | |||||
| total | 42 (12.2) | 47 (14.6) | 8 (12.3) | 0.64 | 0.81 |
| UP/Cr >0.22b | 33 (31.4) | 36 (34.6) | 7 (43.8) | 0.63 | 0.39 |
| Death | |||||
| total | 4 (1.2) | 3 (0.9) | 2 (3.1) | 0.35 | 0.19 |
| UP/Cr >0.22b | 1 (1.0) | 0 (0.0) | 1 (6.3) | 0.14 | 0.14 |
| ESRD or death | |||||
| total | 46 (13.3) | 50 (15.5) | 10 (15.4) | 0.71 | 0.83 |
| UP/Cr >0.22b | 34 (32.4) | 36 (34.6) | 8 (50.0) | 0.40 | 0.19 |
| GFR, ESRD or death | |||||
| total | 81 (23.5) | 79 (24.5) | 12 (18.5) | 0.57 | 0.32 |
| UP/Cr >0.22b | 49 (46.7) | 50 (48.1) | 9 (56.3) | 0.79 | 0.50 |
a
Data are n (%).
b
A baseline ratio of 0.22 corresponds approximately to proteinuria of 300 mg/d. For the end point death, the Fisher exact test was used because expected cell counts were <5.